Rocket Pharmaceuticals, Inc. $RCKT Holdings Cut by Privium Fund Management B.V.

Privium Fund Management B.V. lowered its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 60.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 170,146 shares of the biotechnology company’s stock after selling 262,614 shares during the period. Privium Fund Management B.V. owned about 0.16% of Rocket Pharmaceuticals worth $597,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of RCKT. Monaco Asset Management SAM lifted its holdings in Rocket Pharmaceuticals by 538.8% in the third quarter. Monaco Asset Management SAM now owns 2,892,261 shares of the biotechnology company’s stock worth $9,429,000 after acquiring an additional 2,439,494 shares during the last quarter. MPM Bioimpact LLC lifted its holdings in Rocket Pharmaceuticals by 141.2% in the second quarter. MPM Bioimpact LLC now owns 3,903,081 shares of the biotechnology company’s stock worth $9,563,000 after acquiring an additional 2,284,816 shares during the last quarter. Qube Research & Technologies Ltd raised its holdings in shares of Rocket Pharmaceuticals by 690.8% during the second quarter. Qube Research & Technologies Ltd now owns 1,548,262 shares of the biotechnology company’s stock valued at $3,793,000 after buying an additional 1,352,469 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Rocket Pharmaceuticals by 52.0% during the third quarter. Millennium Management LLC now owns 3,570,391 shares of the biotechnology company’s stock valued at $11,639,000 after buying an additional 1,221,554 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Rocket Pharmaceuticals by 73.6% during the third quarter. JPMorgan Chase & Co. now owns 2,097,033 shares of the biotechnology company’s stock valued at $6,836,000 after buying an additional 889,231 shares during the last quarter. Institutional investors own 98.39% of the company’s stock.

Insider Buying and Selling

In related news, General Counsel Martin Wilson sold 12,253 shares of the firm’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $3.31, for a total value of $40,557.43. Following the completion of the transaction, the general counsel owned 683,376 shares of the company’s stock, valued at approximately $2,261,974.56. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Gaurav Shah sold 12,279 shares of the firm’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $3.31, for a total transaction of $40,643.49. Following the completion of the transaction, the chief executive officer directly owned 1,052,045 shares of the company’s stock, valued at $3,482,268.95. This represents a 1.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 29,415 shares of company stock valued at $97,398 in the last ninety days. Company insiders own 21.30% of the company’s stock.

Rocket Pharmaceuticals Trading Down 1.9%

Rocket Pharmaceuticals stock opened at $3.54 on Wednesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 6.38 and a current ratio of 6.38. The firm has a market cap of $386.28 million, a price-to-earnings ratio of -1.76 and a beta of 0.52. Rocket Pharmaceuticals, Inc. has a 1 year low of $2.19 and a 1 year high of $7.77. The firm’s 50 day moving average price is $4.11 and its two-hundred day moving average price is $3.69.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.04. During the same quarter last year, the business posted ($0.62) earnings per share. On average, research analysts predict that Rocket Pharmaceuticals, Inc. will post -1.68 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on RCKT shares. Lifesci Capital raised Rocket Pharmaceuticals to a “strong-buy” rating in a report on Thursday, February 26th. Cantor Fitzgerald lifted their price target on Rocket Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Friday, February 27th. Wall Street Zen cut Rocket Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, March 8th. Chardan Capital reaffirmed a “buy” rating and set a $11.00 price target on shares of Rocket Pharmaceuticals in a report on Friday, March 27th. Finally, Bank of America lifted their price target on Rocket Pharmaceuticals from $8.00 to $9.00 and gave the company a “buy” rating in a report on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $13.86.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.